Adjuvant Capital
Adjuvant Capital is a New York/Zürich-based venture capital firm founded in 2018 that manages $300 million to invest in clinical-stage vaccines, therapeutics, and diagnostics targeting high-burden global health challenges in low- and middle-income countries. Backed by limited partners including the Bill & Melinda Gates Foundation, Novartis, and the IFC, the firm employs a dual-mandate impact investment model that seeks both financial returns and measurable public health outcomes.
“It will pay up to $780 million for LimmaTech, a Swiss firm focused on bacterial pathogens like Staphylococcus aureus. It had raised $40m from firms like Tenmile, Repair Impact Fund, AXA Investment Managers, Novo Holdings, Adjuvant Capital and CARB-X.”
AI-extracted from podcast / newsletter / paper summaries. May contain errors.